Patients receiving peritoneal dialysis have greater rates of neurocognitive impairment than the general population, according to results published in Nephrology. Investigators conducted a cross-sectional cohort study of 149 patients receiving peritoneal dialysis at a single center between 2016 and 2020. Neurocognitive screening was conducted with Addenbrooke’s Cognitive Examination Revised (ACE-R) with incorporated Mini-Mental State Examination (MMSE). Patients on peritoneal dialysis did worse on ACE-R screening compared with the general population, with discrepancies observed for all cognitive domains. Among patients without cerebrovascular disease, attention and language domains were comparable to the general population. The MMSE identified cognitive impairment in 2% of patients, significantly fewer than the ACE-R (32%). Age, gender, diabetes status, and depression were associated with decreased neurocognitive screening performance (P<0.05). Being on dialysis for more than 12 months conferred poorer cognitive performance, while residual renal function was protective. “Patients on [peritoneal dialysis] have higher prevalence of [neurocognitive impairment] than the general population, primarily with impairments in memory, fluency, and visuospatial reasoning,” the researchers wrote.

Psoriasis Not Tied to MI in Patients With ESRD

Among individuals with end-stage renal disease (ESRD), psoriasis is not associated with an increased risk for myocardial infarction (MI), according to a study published in the American Journal of the Medical Sciences. Naomi Siddiquee, MD-candidate, and colleagues used the United States Renal Data System to identify 1.06 million patients with ESRD starting dialysis between 2004 and 2015. In the whole cohort, 0.6% had psoriasis and 17.1% had MI. However, among 6,823 patients with psoriasis, 24% had an MI. In unadjusted models, psoriasis was associated with an increased risk for MI (OR, 1.34; 95% CI, 1.26-1.42), but when controlling for demographics, dialysis modality,
access type, and comorbidities, psoriasis was not associated with MI (OR, 0.95; 95% CI, 0.89- 1.01). “Contrary to prior research in the general population, in the ESRD population, psoriasis was not associated with an increased risk of MI after controlling for various demographic and clinical parameters,” Siddiquee and colleagues wrote.